Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2011 pp 799–812Cite as

Parkinsonmittel

  • Chapter

  • 1290 Accesses

Zusammenfassung

Die Parkinsonsche Krankheit ist eine fortschreitende neurologische Erkrankung des extrapyramidalmotorischen Systems, von der 1% der Bevölkerung über 65 Jahre betroffen ist. Ursache ist eine in ihrer Ätiologie unbekannte Degeneration von Nervenzellen in der Substantia nigra, die zu einem „striatalen“ Dopaminmangelsyndrom führt und mit einer erhöhten cholinergen Aktivität einhergeht. Die klassischen Symptome sind Akinese, Rigor und Tremor. Daneben treten zunehmend nichtmotorische Symptome wie vegetative und kognitive Störungen ins Blickfeld, die mit den derzeit verfügbaren Therapieoptionen weniger gut beeinflussbar sind (Übersicht bei Lees et al. 2009).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahlskog JE, Uitti RJ (2010): Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74: 1143–1148.

    Article  PubMed  CAS  Google Scholar 

  • Anonymus (2008): Rotigotine: Parkinson’s disease: a step backward. Prescrire Int 17: 60.

    Google Scholar 

  • Arnold G, Kupsch A (2000): Hemmung der Catechol-O-Methyltransferase. Optimierung der dopaminergen Therapie beim idiopathischen Parkinsonsyndrom mit Entacapone. Nervenarzt 71: 78–83.

    Article  PubMed  CAS  Google Scholar 

  • Chen JJ, Swope DM (2005): Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878–894.

    Article  PubMed  CAS  Google Scholar 

  • Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson‘s disease. Cochrane Database Syst Rev. 2003;(1):CD003468.

    Google Scholar 

  • Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson‘s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554.

    Google Scholar 

  • Deutsche Gesellschaft fur Neurologie (2008): Parkinson-Syndrome. Internet: www.dgn.org/images/stories/dgn/leitlinien/LL2008/ll08kap_009.pdf

  • European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf

  • European Medicines Agency (EMA) (2006): Rotigotin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.eu.int/humandocs/PDFs/EPAR/neupro/062606de1.pdf

  • Fahn S and the Parkinson Study Group (2005): Does levodopa slow or hasten the rate of progression of Parkinson‘s disease? J Neurol 252 (Suppl 4): IV37-IV42.

    Article  PubMed  Google Scholar 

  • Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999): Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908–1910.

    PubMed  CAS  Google Scholar 

  • Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators (2007): Rotigotine transdermal patch in early Parkinson‘s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404.

    Article  PubMed  Google Scholar 

  • Huntington Study Group (2006): Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366–372.

    Article  Google Scholar 

  • Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K (2004): Monoamine oxidase type B inhibitors in early Parkinson’s disease: metaanalysis of 17 randomised trials involving 3525 patients. BMJ 329: 593–599.

    Article  PubMed  CAS  Google Scholar 

  • Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003; (2):CD003735.

    Google Scholar 

  • Koller WC, Tse W (2004): Unmet medical needs in Parkinson’s disease. Neurology 62 (Suppl 1): S1–8.

    Google Scholar 

  • Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311: 1602–1607.

    PubMed  CAS  Google Scholar 

  • Lees AJ, Hardy J, Revesz T (2009): Parkinson’s disease. Lancet 373: 2055–2066. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687–1694.

    Article  PubMed  CAS  Google Scholar 

  • Mejer Nielsen B (1983): Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372–375.

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010): Missing pieces in the Parkinson’s disease puzzle. Nat Med 16: 653–661.

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (2009): A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361: 1268–1278.

    Article  PubMed  CAS  Google Scholar 

  • Parkinson Study Group (2004): A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566.

    Article  Google Scholar 

  • Parkinson Study Group (2005): A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241–248.

    Article  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491.

    Article  PubMed  CAS  Google Scholar 

  • Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005): Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947–954.

    Article  PubMed  CAS  Google Scholar 

  • Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158.

    Article  PubMed  CAS  Google Scholar 

  • Scottish Intercollegiate Guidelines Network (2010): Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline. Internet: www.sign.ac.uk/pdf/sign113.pdf

  • Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50 (Suppl 6): S18-S22; discussion S44–S48.

    PubMed  CAS  Google Scholar 

  • Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010): Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68: 18–27.

    Article  PubMed  CAS  Google Scholar 

  • The Parkinson Study Group (1993): Effects of tocopherol and deprenyl on the progression of disability in early parkinson‘s disease. N Engl J Med 328: 176–183.

    Article  Google Scholar 

  • The Parkinson Study Group (2004): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2011). Parkinsonmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21992-4_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21992-4_38

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21991-7

  • Online ISBN: 978-3-642-21992-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation